Bayer weighs merger options
Bayer AG, Wuppertal, Germany, indicated that it may be considering a merger with another major pharmaceutical company.
Bayer AG, Wuppertal, Germany, indicated that it may be considering a merger with another major pharmaceutical company.
In an interview with the Wall Street Journal in June, Horst Meyer, the general manager of Bayer's pharmaceuticals business group, said the company wants to boost its global market share from its current state of 2.3% to more than 4%. The only way that the company can achieve this growth, Meyer told the Journal, is through "business combinations."
Despite achieving sales growth of 30% in the United States in 1997 - almost twice as much as the business group as a whole - Bayer did not move into the top 10 in industry ranking. It currently stands in twelfth place, behind Abbott Laboratories, according to Plymouth, PA-based IMS America.
In a recent press conference, Meyer indicated that marketing alliances are and will continue to be a standard way for Bayer to sell its products in North America.
The company's most significant alliances "involve the licensing of nisoldipine, a calcium antagonist, to Zeneca, and of miglitol, an antidiabetic drug, to Sanofi and Sanwa," Meyer said. Bayer also comarkets products with Smith-Kline Beecham and Fournier.
Meyer did not indicate whether one or several of these business partners was a possible candidate for a merger. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
